A5116337638- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Brain Metastases and Treatment
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Nutrition and Health in Aging
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Advanced Optical Sensing Technologies
- Impact of Light on Environment and Health
- Transcranial Magnetic Stimulation Studies
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Quinazolinone synthesis and applications
- Advanced Breast Cancer Therapies
- Cancer Mechanisms and Therapy
- Immunotherapy and Immune Responses
- Lung Cancer Diagnosis and Treatment
- Cardiac Arrhythmias and Treatments
- Colorectal Cancer Surgical Treatments
Nagoya Medical Center
2018-2025
National Hospital Organization
2020-2025
National Cancer Center Hospital East
2023-2025
National Cancer Center
2024-2025
Saitama Medical University
2025
Social Insurance Saitama Chuo Hospital
2025
Toshiba (Japan)
1988-2004
National Center of Neurology and Psychiatry
2003
Kyoto University
2000
Abstract Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2-positive BM. Data were analyzed 104 administered T-DXd. Overall response rate (ORR), progression-free survival (PFS), overall (OS), intracranial (IC)-ORR, IC-PFS evaluated. ORR by investigator assessment was 55.7% (total population)....
433 Background: The standard treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) is neoadjuvant chemotherapy followed by surgery. However, the efficacy and safety of patients aged 76 or older have not been established because JCOG1109 trial, which current care, was limited to younger than years. In our hospital, even are treated with docetaxel, cisplatin, 5-FU (DCF) / leucovorin, oxaliplatin, docetaxel (FLOT), if patient's general condition organ function...
425 Background: Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) based on results of JCOG 0303 study. However, prognosis in this population remains poor with a median overall survival (OS) 13.1 months, and fistula formation was reported about 20% patients who received dCRT. In such circumstance, more effective safer strategy, as induction chemotherapy followed by conversion surgery or dCRT, developed....
384 Background: The standard neoadjuvant treatment in Japan for resectable locally advanced esophageal squamous cell carcinoma (ESCC) is docetaxel (DTX) + cisplatin (CDDP) 5-fluorouracil (5-FU) (DCF) based on the results of JCOG1109 study. Neoadjuvant DCF therapy administrated triweekly; first week a hospital, and remaining two weeks at hom. After administration therapy, patients might suffer from febrile neutropenia or gastrointestinal symptoms such as nausea, vomiting, constipation,...
Cisplatin-based chemotherapy is the standard advanced esophageal squamous cell carcinoma (ESCC) treatment. However, 5-fluorouracil plus L-leucovorin and oxaliplatin (FOLFOX) regimen available in Japan as an alternative to cisplatin-based chemotherapy, but its efficacy safety remain unclear. Hence, we aimed evaluate patients with ESCC who received FOLFOX therapy retrospectively. Patients at 18 institutions between April 2019 October 2020 were included. Fifty-two first-line treatment, while 39...
Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) provides survival benefits in non-small cell lung cancer (NSCLC) with EGFR mutations. The acquired v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation is present ⁓3% of cases as a resistance mechanism to osimertinib, third-generation TKI. However, there no consensus on the optimal therapy for patients osimertinib-resistant EGFR-mutated NSCLC harboring BRAF V600E mutation. Here, we case oldest patient...
Abstract Background: Brain metastases (BM) occur in 20%-50% of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC), and their presence is a poor prognostic factor. Leptomeningeal carcinomatosis (LMC) occurs 12%–43% pts MBC. Therapeutic options for BC BM and/or LMC are limited. Results the DESTINY-Breast01 DESTINY-Breast03 studies have shown clinical benefit trastuzumab deruxtecan (T-DXd) HER2+ MBC stable BM; however, study populations were small did not include active...
Malnutrition and cachexia occur commonly in patients with advanced gastric cancer (AGC). This study elucidated the effect of nutritional support (NS) on survival outcomes among AGC undergoing chemotherapy. We retrospectively evaluated new cases at our institute between January 2015 2021. Inclusion criteria were unresectable or recurrent chemotherapy-treated adenocarcinoma, ECOG performance status (PS) 0-2, adequate organ function. Time to treatment failure (TTF) overall (OS) evaluated,...
A nephrotic patient with membranoproliferative glomerulonephritis type II (MPGN II) was treated cyclosporin (CSA) and alternate-day low-dose prednisolone. This developed the syndrome twice. The second episode of steroid resistant, therefore this a CSA regimen. During treatments prednisolone CSA, recovered from syndrome. We conclude that therapy may be effective for patients steroid-resistant caused by MPGN II.
Treatment options for patients with relapsed/refractory small cell lung cancer (R/R SCLC) are limited, and the efficacy of salvage therapies heavily treated should be assessed. Here, we evaluated paclitaxel (PTX) in R/R SCLC patients.A single-institute retrospective chart review was conducted. The primary endpoint overall survival (OS), whereas secondary endpoints were progression-free (PFS), response rate, disease control rate (DCR), safety.Thirty-one (median age, 69 [range, 56-80] years)...
329 Background: Although nivolumab plus ipilimumab (Nivo+Ipi) is strongly recommended as 1st-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC), tumor proportion score (TPS) should be considered. Despite the efficacy, who received Nivo+Ipi often experienced serious immune related adverse events (irAEs). However, there are few data on safety and short-term efficacy of in real world. Methods: We retrospectively collected pts ESCC between May 2022 to July 2023...
Background: There are no established guidelines for the management of apocrine carcinomas breast; they treated as a non-specific type breast cancer. Case Report: We report on case 40-year-old man who developed primary mediastinal carcinoma overexpressing human epidermal growth factor-2 (HER2). The patient initially underwent complete resection mature teratoma with focal component. Two years after surgery, relapse was detected in multiple lymph nodes. He received induction chemotherapy...
Abstract We report an autopsied case of a 21‐gestational‐week fetus with duplication the proteolipid protein (PLP) gene ( PLP1 ). An immunohistochemical study, which can detect specific expression PLP, myelin basic protein, myelin‐associated glycoprotein, and platelet‐derived growth factor receptor α subunit in brain tissues, showed that myelination was almost same as age‐matched controls. This result suggests development migration oligodendrocyte is normal Pelizaeus–Merzbacher disease until...
112 Background: Ramucirumab (RAM) plus FOLFIRI has been considered as the standard care of second-line treatment in metastatic colorectal cancer (mCRC). However, there have few data which prospectively evaluated efficacy and safety RAM or other anti-VEGF drugs after anti-EGFR antibody therapy RAS wild-type mCRC. We therefore investigated patients with mCRC previously treated oxaliplatin-containing chemotherapy antibody. Methods: The JACCRO CC-16 was a multicenter, phase 2 trial to evaluate...